**H.6.3.2** **Anti-VEGF + steroids vs anti-VEGF**

| Number of RCTs | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Sample size | Effect (95%CI) | Quality |
|---|---|---|---|---|---|---|---|---|
| **Anti-VEGF vs anti-VEGF steroids** | | | | | | | | |
| **BCVA (ETDRS letters >3 months) - postive values favour combination** | | | | | | | | |
| 3 (Ahmadieh; Kuppermann; Ranchod) | RCT | Not serious[1] | Not serious | Serious[2] | Not serious | 267 | MD 0.82 (-1.91, 3.55) | MODERATE |
| **BCVA (proportion gain ≥15 letter, >3 months) - values greater than 1 favour combination** | | | | | | | | |
| 2 (Kuppermann; Ranchod) | RCT | Serious[3] | Not serious | Serious[2] | Very serious[4] | 152 | RR 1.20 (0.53, 2.70) | VERY LOW |
| **Total number of injections (>3 months) - positive values favour combination** | | | | | | | | |
| 1 (Ranchod) | RCT | Serious[3] | N/A | Serious[2] | Serious[5] | 37 | MD -0.50 (-1.30, 0.30) | VERY LOW |
| **Proportion needing retreatment (>3 months) - values greater than 1 favour combination** | | | | | | | | |
| 1 (Ahmadieh) | RCT | Serious[3] | N/A | Serious[2] | Serious[6] | 115 | RR 0.65 (0.42, 1.00) | VERY LOW |
| **Proportion having ocular adverse events - values greater than 1 favour combination** | | | | | | | | |
| 1 (Kuppermann) | RCT | Serious[3] | N/A | Serious[2] | Serious[6] | 333 | RR 1.20 (0.91, 1.59) | VERY LOW |

1. Some individual studies at high-risk of bias, but overall risk of bias rated low due to consistency of effect size estimates between high and low quality studies.
2. Downgraded one level for unclear about cataract status of study population.
3. Downgraded one level for study design (open label, single blinded)
4. Downgraded one level for confidence interval crossing 2 lines of a defined minimal important difference.
5. Downgraded one level for non-significant effect.
6. Downgraded one level for confidence interval crossing 1 line of a defined minimal important difference.

*visual acuity outcome reported in the study used logMAR, and was converted to number of letters (logMAR=no. of letters × -0.02).

## Meta-analysis: anti-VEGF + steroids vs anti-VEGF

## Visual acuity

### Letters (>3 month follow-up)



### Letters gained (proportion 15 or more letters)